PDF herunterladen
Nuklearmedizin
DOI: 10.1055/a-2578-7222
Case Report

[99mTc]Tc-PSMA SPECT/CT is a promising tool in the staging of renal cell carcinoma

Marcel Baehr
1   Johannes-Wesling Hospital Minden, Department of Radiology, Neuroradioloy and Nuclear Medicine, Ruhr University Bochum, Bochum, Germany (Ringgold ID: RIN9142)
,
Isabell Dietrich
2   Department of Nuclear Medicine, Klinikum Frankfurt Oder GmbH, Frankfurt (Oder), Germany (Ringgold ID: RIN40672)
,
Knut Liepe
2   Department of Nuclear Medicine, Klinikum Frankfurt Oder GmbH, Frankfurt (Oder), Germany (Ringgold ID: RIN40672)
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Introduction

Clear cell renal cell carcinoma (ccRCC) accounts for 94 % of metastasized renal cell carcinomas (RCC) [1] and frequently exhibits a strongly upregulated prostate-specific membrane antigen (PSMA) expression [2]. At primary diagnosis of RCC, regional lymph node metastases and distant metastases are present in 16 % and 15 % of cases, respectively [3]. The most common sites of distant metastases are lung (70 %), distant lymph nodes (45 %) and bone (32 %). In the staging of RCC, PSMA positron emission tomography/computed tomography (PET/CT) detects additional metastases in 25 % of cases and changes therapeutic management in 49 % [1]. In biochemical recurrence of prostate cancer, [99mTc]Tc-MIP-1404 has confirmed detection rates similar to PSMA PET/CT [4]. Consequently, [99mTc]Tc-based PSMA ligands are emerging as a potential alternative in order to ensure excellent healthcare service in circumstances where PSMA PET/CT is not accessible.



Publikationsverlauf

Eingereicht: 01. April 2025

Angenommen: 08. April 2025

Artikel online veröffentlicht:
12. Mai 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Bellin MF, Valente C, Bekdache O. et al. Update on Renal Cell Carcinoma Diagnosis with Novel Imaging Approaches. Cancers (Basel) 2024; 16
    CrossrefPubMedSuche in Google Scholar
  • 2 Gasparro D, Scarlattei M, Silini EM. et al. High Prognostic Value of (68)Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry. Diagnostics (Basel) 2023; 13
    CrossrefPubMedSuche in Google Scholar
  • 3 Institute NC. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2022). In: DCCPS, Surveillance Research Program; released March 2024 . www.seer.cancer.gov/popdata
  • 4 Schmidkonz C, Hollweg C, Beck M. et al. (99m) Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. The Prostate 2018; 78: 54-63
    CrossrefPubMedSuche in Google Scholar
  • 5 Cook GR, Wong W, Sanghera B. et al. Eligibility for (177)Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2023; 64: 227-231
    CrossrefPubMedSuche in Google Scholar
  • 6 Aggarwal P, Singh H, Das CK. et al. Potential role of (68)Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. Eur J Radiol 2024; 170: 111218
    CrossrefPubMedSuche in Google Scholar
  • 7 Cesana B, Cochet C, Filhol O. New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities. Int J Cancer 2025; 156: 475-487
    CrossrefPubMedSuche in Google Scholar